Monitor cash burn rate and upcoming clinical trial readouts in 2026; the recent capital raise may not be sufficient given the increased R&D spend and lack of revenue generation.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 1 $24.86entry
- T+1 · 8mo ago +2.90%α +2.82% · $25.58
- T+5 · 7mo ago +36.36%α +32.60% · $33.90
- T+20 · 7mo ago +12.75%α +3.03% · $28.03
- T+60 · 5mo ago −14.24%α −27.62% · $21.32
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Forte Biosciences reported a net loss per share of $(4.71) for FY 2025, missing consensus estimates, with R&D expenses nearly tripling due to clinical trial advancement. This follows a recent $150M follow-on offering, raising concerns about capital efficiency.
Key Financial Metrics
Key Facts
- Net loss per share was $(4.71) for FY 2025, missing consensus of $-1.16
- R&D expenses increased to $58.2M from $21.2M in 2024 due to clinical trials
- Cash and cash equivalents decreased to $77.0M from $93.4M in Q3 2025
- Recent $150M follow-on offering completed just 12 days prior to earnings
Financial Impact
Net loss of $69.375M vs consensus expectations of $20.0M loss
Risk Factors
- High cash burn rate may necessitate additional capital raises
- Clinical trial failures could further impact stock performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-135767 |
| Document: d63145d8k.htm | 0001193125-26-135767 |
| Document: 0001193125-26-135767-index-headers.html | 0001193125-26-135767 |
| Document: 0001193125-26-135767-index.html | 0001193125-26-135767 |
| Document: 0001193125-26-135767.txt | 0001193125-26-135767 |
| 8-K Data (Synthetic) | 0001193125-26-135767 |
Track record
15 reports on FBRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
- Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
- Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
- Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
- Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
- Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
- Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
- Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers